Amalgamated Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Amalgamated Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$274K	Buy	+5,945	New	+$321K	﹤0.01%	1768

Other funds holding ZNTL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Amalgamated Financial's ZNTL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2022: 5,945 shares worth $274K. The stake represents ﹤0.01% of the portfolio and ranks #1768 among its holdings.

128 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

Amalgamated Financial held 5,945 shares of Zentalis Pharmaceuticals worth $274K as of Q1 2022.
Zentalis Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Zentalis Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1768 holding.
128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.